Table 3 Characteristics of development and validation cohorts for those aged 80–95 years (before imputation)
|  | Development cohort n = 130,382 Median follow-up 3.76 years (IQR, 1.71–5 years) Dementia events n = 7,104 | Validation cohort n = 38,084 Median follow-up 3.92 years (IQR, 1.75–5 years) Dementia events n = 1,923 | ||||
|---|---|---|---|---|---|---|
| Â | Obs | Mean | SD | Obs | Mean | SD |
Baseline age, years | 130,382 | 84.8 | 3.93 | 38,084 | 84.9 | 3.97 |
Baseline total cholesterol, mmol/L | 26,841 | 4.99 | 1.19 | 6,785 | 5.08 | 1.21 |
Baseline HDL cholesterol, mmol/L | 16,630 | 1.50 | 0.44 | 4,066 | 1.49 | 0.44 |
Baseline weight, kg | 31,272 | 67.1 | 14.0 | 8,038 | 67.2 | 13.8 |
Baseline systolic blood pressure, mmHg | 78,979 | 146.9 | 19.8 | 22,347 | 147.5 | 19.8 |
Height, m | 62,622 | 1.62 | 0.10 | 17,616 | 1.62 | 0.10 |
Baseline BMI, kg/m2 | 24,091 | 25.7 | 4.65 | 6,213 | 25.7 | 4.53 |
Baseline lipid ratio | 16,566 | 3.49 | 1.10 | 4,054 | 3.57 | 1.13 |
| Â | Obs | Freq | % | Obs | Freq | % |
Sex | 130,382 | Â | Â | 38,084 | Â | Â |
Men | Â | 44,286 | 34.0 | Â | 13,017 | 34.2 |
Women | Â | 86,096 | 66.0 | Â | 25,067 | 65.8 |
Local area deprivation score (quintiles) | 130,382 | Â | Â | 38,084 | Â | Â |
1 (=least deprived) | Â | 26,643 | 20.4 | Â | 10,048 | 26.4 |
2 | Â | 30,143 | 23.1 | Â | 9,307 | 24.4 |
3 | Â | 28,970 | 22.2 | Â | 7,830 | 20.6 |
4 | Â | 26,758 | 20.5 | Â | 6,644 | 17.5 |
5 (=most deprived) | Â | 17,868 | 13.7 | Â | 4,255 | 11.2 |
Baseline smoking status | 113,391 | Â | Â | 32,702 | Â | Â |
Never | Â | 63,684 | 56.2 | Â | 19,389 | 59.3 |
Past | Â | 39,778 | 35.1 | Â | 10,697 | 32.7 |
Current | Â | 9,929 | 8.8 | Â | 2,616 | 8.0 |
History of very heavy drinking/alcohol problem | 130,382 | 921 | 0.7 | 38,084 | 250 | 0.7 |
History of diabetes | 130,382 | 12,762 | 9.8 | 38,084 | 3,331 | 8.8 |
History of coronary heart disease | 130,382 | 28,190 | 21.6 | 38,084 | 8,281 | 21.7 |
History of stroke or transient ischemic attack | 130,382 | 20,221 | 15.5 | 38,084 | 5,824 | 15.3 |
History of atrial fibrillation | 130,382 | 14,518 | 11.1 | 38,084 | 4,293 | 11.3 |
Depression or use of anti-depressants at baseline | 130,382 | 17,201 | 13.2 | 38,084 | 4,886 | 12.8 |
Anxiety or use of anxiolytics at baseline | 130,382 | 5,953 | 4.6 | 38,084 | 1,816 | 4.8 |
Use of anti-hypertensive drugs at baseline | 130,382 | 58,323 | 44.7 | 38,084 | 16,396 | 43.1 |
Use of statins at baseline | 130,382 | 16,546 | 12.7 | 38,084 | 4,111 | 10.8 |
Use of hypnotics at baseline | 130,382 | 14,121 | 10.8 | 38,084 | 4,137 | 10.9 |
Use of NSAIDs (other than aspirin) at baseline | 130,382 | 15,056 | 11.6 | 38,084 | 4,430 | 11.6 |
Use of aspirin at baseline | 130,382 | 41,448 | 31.8 | 38,084 | 11,830 | 31.1 |